Spots Global Cancer Trial Database for tafasitamab
Every month we try and update this database with for tafasitamab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) | NCT04809467 | Chronic Lymphoc... Non Hodgkin Lym... | tafasitamab parsaclisib | 18 Years - | Incyte Corporation | |
| Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia | NCT05453500 | B Acute Lymphob... | Bone Marrow Asp... Cyclophosphamid... Doxorubicin Etoposide Prednisone Rituximab Tafasitamab Vincristine | 18 Years - | University of Washington | |
| Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma | NCT05351593 | CNS Lymphoma Primary Central... Secondary Centr... | Tafasitamab Lenalidomide | 18 Years - | University of California, San Francisco | |
| Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL | NCT04134936 | Diffuse Large B... | Tafasitamab Tafasitamab plu... | 18 Years - | MorphoSys AG | |
| A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer. | NCT05205252 | Relapsed Hemato... Refractory Hema... | Tazemetostat Tafasitamab Lenalidomide Acalabrutinib Daratumumab (In... Mosunetuzumab Daratumumab (Su... Hyaluronidase-F... Pomalidomide Dexamethasone 2... | 18 Years - | Ipsen | |
| Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients | NCT04824092 | Diffuse Large B... | Tafasitamab Lenalidomide Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone Tafasitamab pla... Lenalidomide pl... | 18 Years - 80 Years | MorphoSys AG | |
| Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | NCT05910801 | Recurrent Mantl... Refractory Mant... | Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Lenalidomide Lumbar Puncture Magnetic Resona... Positron Emissi... Tafasitamab Venetoclax | 18 Years - | Academic and Community Cancer Research United | |
| A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | NCT02763319 | Diffuse Large B... | Rituximab (RTX) Tafasitamab Bendamustine (B... | 18 Years - | MorphoSys AG | |
| Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients | NCT04824092 | Diffuse Large B... | Tafasitamab Lenalidomide Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone Tafasitamab pla... Lenalidomide pl... | 18 Years - 80 Years | MorphoSys AG | |
| Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL | NCT05583071 | Non-Hodgkin Lym... | Tafasitamab Lenalidomide Rituximab Methotrexate | 18 Years - 99 Years | University of Cologne | |
| A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) | NCT04809467 | Chronic Lymphoc... Non Hodgkin Lym... | tafasitamab parsaclisib | 18 Years - | Incyte Corporation | |
| A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL | NCT05615636 | Hodgkin Lymphom... B-Cell Lymphoma Relapsed B-cell... | Mosunetuzumab Polatuzumab ved... Tafasitamab Lenalidomide | 18 Years - | M.D. Anderson Cancer Center | |
| Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma | NCT05455697 | Diffuse Large B... Grade 3b Follic... High Grade B-Ce... | Bone Marrow Bio... Cyclophosphamid... Doxorubicin Prednisone Retifanlimab Rituximab and H... Tafasitamab Vincristine Bone Marrow Asp... Multigated Acqu... Fludeoxyglucose... Positron Emissi... Computed Tomogr... Biospecimen Col... Polatuzumab Ved... | 18 Years - | University of Washington | |
| Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL | NCT02399085 | Diffuse Large B... | Tafasitamab Lenalidomide | 18 Years - | MorphoSys AG | |
| Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL) | NCT05328102 | Diffuse Large-c... | Plamotamab Tafasitamab Lenalidomide | 18 Years - | Xencor, Inc. | |
| Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) | NCT04607772 | Relapsed or Ref... | Selinexor Rituximab Bendamustine Polatuzumab Ved... Ibrutinib Lenalidomide Tafasitamab Venetoclax Gemcitabine Oxaliplatin | 18 Years - | Karyopharm Therapeutics Inc | |
| Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma | NCT05351593 | CNS Lymphoma Primary Central... Secondary Centr... | Tafasitamab Lenalidomide | 18 Years - | University of California, San Francisco | |
| A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL | NCT05615636 | Hodgkin Lymphom... B-Cell Lymphoma Relapsed B-cell... | Mosunetuzumab Polatuzumab ved... Tafasitamab Lenalidomide | 18 Years - | M.D. Anderson Cancer Center | |
| Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL | NCT04134936 | Diffuse Large B... | Tafasitamab Tafasitamab plu... | 18 Years - | MorphoSys AG | |
| Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL) | NCT01685008 | Non-Hodgkin Lym... | MOR00208 (forme... | 18 Years - | MorphoSys AG | |
| A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. | NCT04680052 | Follicular Lymp... Marginal Zone L... | tafasitamab rituximab lenalidomide placebo | 18 Years - | Incyte Corporation | |
| Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma | NCT06029309 | Mantle Cell Lym... | Zanubrutinib Tafasitamab | 18 Years - | University of Miami | |
| Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND) | NCT06299553 | DLBCL - Diffuse... | 18 Years - | Incyte Biosciences Italy S.r.l | ||
| A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) | NCT03930953 | Lymphoma, Non-H... | CC-99282 Rituximab Obinutuzumab Tafasitamab Valemetostat | 18 Years - | Celgene | |
| Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma | NCT04161248 | Lymphoma, B-Cel... | Venetoclax Rituximab Injec... Rituximab SC Gemcitabine Dexamethasone Cisplatin Glofitamab Tafasitamab | 16 Years - 65 Years | Canadian Cancer Trials Group | |
| Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) | NCT04607772 | Relapsed or Ref... | Selinexor Rituximab Bendamustine Polatuzumab Ved... Ibrutinib Lenalidomide Tafasitamab Venetoclax Gemcitabine Oxaliplatin | 18 Years - | Karyopharm Therapeutics Inc | |
| To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL) | NCT04661007 | Non Hodgkins Ly... Diffuse Large B... | tafasitamab lenalidomide parsaclisib R-CHOP | 18 Years - | Incyte Corporation | |
| Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma | NCT05626322 | Diffuse Large B... | Maplirpacept Tafasitamab Lenalidomide | 18 Years - | Pfizer | |
| Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma | NCT05455697 | Diffuse Large B... Grade 3b Follic... High Grade B-Ce... | Bone Marrow Bio... Cyclophosphamid... Doxorubicin Prednisone Retifanlimab Rituximab and H... Tafasitamab Vincristine Bone Marrow Asp... Multigated Acqu... Fludeoxyglucose... Positron Emissi... Computed Tomogr... Biospecimen Col... Polatuzumab Ved... | 18 Years - | University of Washington | |
| Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | NCT05910801 | Recurrent Mantl... Refractory Mant... | Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Lenalidomide Lumbar Puncture Magnetic Resona... Positron Emissi... Tafasitamab Venetoclax | 18 Years - | Academic and Community Cancer Research United | |
| Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND) | NCT05429268 | Large B-Cell Ly... Diffuse Large B... | Tafasitamab Lenalidomide | 18 Years - 99 Years | Incyte Corporation | |
| Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma | NCT05626322 | Diffuse Large B... | Maplirpacept Tafasitamab Lenalidomide | 18 Years - | Pfizer | |
| Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL | NCT05583071 | Non-Hodgkin Lym... | Tafasitamab Lenalidomide Rituximab Methotrexate | 18 Years - 99 Years | University of Cologne | |
| Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | NCT05910801 | Recurrent Mantl... Refractory Mant... | Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Lenalidomide Lumbar Puncture Magnetic Resona... Positron Emissi... Tafasitamab Venetoclax | 18 Years - | Academic and Community Cancer Research United |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
